CONNETTIVINA PLUS*CREAM 25G

Connettivina Plus 2 mg/g + 10 mg/g cream
Hyaluronic acid sodium salt + silver sulfadiazine

What it is and what it is used for
Connettivina Plus 2 mg/g + 10 mg/g cream contains two active ingredients: hyaluronic acid sodium salt and silver sulfadiazine, and belongs to a class of medicines called healing and disinfectant agents.

Hyaluronic acid is a substance naturally produced by our body. The local application of hyaluronic acid facilitates the healing process of lesions.
Silver sulfadiazine is an active ingredient belonging to the family of sulfonamide antibiotics, capable of blocking replication mechanisms and thus counteracting the formation of infections.

Connettivina Plus 2 mg/g + 10 mg/g cream is indicated for the local treatment of wounds in the initial stage (before the skin breaks) and for the treatment of mild burns (first and second-degree burns).

What you need to know before taking the medicine
Do not use Connettivina Plus:
- if you are allergic to the active ingredient or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions
Talk to your doctor or pharmacist before using Connettivina Plus if:
- you have had a hypersensitivity reaction (allergic reaction) after taking sulfonamides;
- you have severe liver problems (liver failure);
- you have severe kidney problems (kidney failure);
- if you are pregnant or breastfeeding.

Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.

After applying CONNETTIVINA PLUS, local reactions (pain, burning, itching), including allergic reactions, may occur.

Following the application of Connettivina Plus to large areas of the skin, you may experience side effects that are usually observed with the oral or injectable (systemic routes) administration of sulfonamide-based medicines (the class of drugs to which sulfadiazine belongs) such as:
- severe kidney problems (kidney failure);
- liver inflammation as a reaction to certain substances to which one is exposed (toxic hepatitis);
- reduction in the number of white blood cells (agranulocytosis and leukopenia) and platelets (thrombocytopenia) circulating in the blood.

Reporting of side effects
If you get any side effects, including any not listed in this leaflet, talk to your doctor or pharmacist. You can also report side effects directly via the national reporting system at: https://www.aifa.gov.it/content/segnalazionireazioni-avverse.
By reporting side effects, you can help provide more information on the safety of this medicine.